This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bert, F.
Right arrow Articles by Branger, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bert, F.
Right arrow Articles by Branger, C.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2003, p. 5147-5152, Vol. 41, No. 11
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.11.5147-5152.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Prevalence, Molecular Epidemiology, and Clinical Significance of Heterogeneous Glycopeptide-Intermediate Staphylococcus aureus in Liver Transplant Recipients

Frédéric Bert,1* Juliette Clarissou,1 François Durand,2 Didier Delefosse,3 Chantal Chauvet,1 Patricia Lefebvre,1 Nicole Lambert,1 and Catherine Branger1

Departments of Microbiology,1 Hepatology,2 Anesthesiology, Hospital Beaujon, Clichy, France3

Received 24 January 2003/ Returned for modification 12 March 2003/ Accepted 5 August 2003

We investigated the prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) isolates in 48 liver transplant recipients infected or colonized with methicillin-resistant S. aureus over a 5-year period. Strains were screened for hGISA on Mueller-Hinton agar containing 5 mg of teicoplanin per liter. Heterogeneous glycopeptide resistance was confirmed by the E-test method with a dense inoculum and a simplified method of population analysis. hGISA strains were found in 13 (27%) of the 48 patients studied. Eleven of the 13 strains shared a common multiresistant phenotype with homogeneous methicillin resistance and gentamicin resistance, and they were closely related according to the results of pulsed-field gel electrophoresis. Only 2 of the 13 patients infected or colonized with hGISA strains had previously received glycopeptide therapy. Most patients were successfully treated with vancomycin, but one patient who failed to respond to vancomycin subsequently died. These results suggest that the high prevalence of hGISA among our patients was due to the clonal spread of a multiresistant strain.

* Corresponding author. Mailing address: Hôpital Beaujon, Service de Microbiologie, 100 Boulevard du Général Leclerc, 92110 Clichy, France. Phone: 33.1.40.87.54.42. Fax: 33.1.40.87.05.50. E-mail: bertfrederic{at}hotmail.com.

Journal of Clinical Microbiology, November 2003, p. 5147-5152, Vol. 41, No. 11
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.11.5147-5152.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Liu, Y., Wang, H., Du, N., Shen, E., Chen, H., Niu, J., Ye, H., Chen, M. (2009). Molecular Evidence for Spread of Two Major Methicillin-Resistant Staphylococcus aureus Clones with a Unique Geographic Distribution in Chinese Hospitals. Antimicrob. Agents Chemother. 53: 512-518 [Abstract] [Full Text]  
  • Rybak, M. J., Leonard, S. N., Rossi, K. L., Cheung, C. M., Sadar, H. S., Jones, R. N. (2008). Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007). J. Clin. Microbiol. 46: 2950-2954 [Abstract] [Full Text]  
  • Rose, W. E., Leonard, S. N., Rossi, K. L., Kaatz, G. W., Rybak, M. J. (2008). Relationships between vancomycin pharmacodynamics and the emergence of vancomycin-intermediate Staphylococcus aureus (VISA) from heterogeneous VISA in an in vitro pharmacodynamic model. J Antimicrob Chemother 0: dkn037v1-6 [Abstract] [Full Text]  
  • Garnier, F., Chainier, D., Walsh, T., Karlsson, A., Bolmstrom, A., Grelaud, C., Mounier, M., Denis, F., Ploy, M.-C. (2006). A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother 57: 146-149 [Abstract] [Full Text]  
  • Song, J.-H., Hiramatsu, K., Suh, J. Y., Ko, K. S., Ito, T., Kapi, M., Kiem, S., Kim, Y.-S., Oh, W. S., Peck, K. R., Lee, N. Y., and the Asian Network for Surveillance of Resistan, (2004). Emergence in Asian Countries of Staphylococcus aureus with Reduced Susceptibility to Vancomycin. Antimicrob. Agents Chemother. 48: 4926-4928 [Abstract] [Full Text]  
  • Huang, V., Brown, W. J., Rybak, M. J. (2004). In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant Staphylococcus aureus and Glycopeptide-Intermediate Susceptible Staphylococci. Antimicrob. Agents Chemother. 48: 2719-2723 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»